For the first time, these kinds of compounds were used in 2001:a revolutionary increase of fl–SMN2 transcript level could be noticed following thesodium butyrate treatment of SMA patients, derived cell lines and SMA knockout transgenic mice[15]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.